PortfoliosLab logoPortfoliosLab logo
ISIN
US81943R1005

Highlights

Market Cap
$5.67B
Enterprise Value
$72.58B
EPS (TTM)
$7.82
PE Ratio
0.97
Total Revenue (TTM)
$287.69B
Gross Profit (TTM)
$31.21B
EBITDA (TTM)
$9.77B
Year Range
$6.83 - $8.32
ROA (TTM)
2.47%
ROE (TTM)
7.52%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

SHPMY Performance Chart

Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) is down 7.7% since the beginning of the year. At $8 per share, SHPMY is trading 8.7% below its 52-week high of $8. Investors who bought $1,000 worth of SHPMY shares 5 years ago would now be looking at an investment worth $820.


Loading charts...

S&P 500 Index

Returns By Period

Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) has returned -7.65% so far this year and 15.56% over the past 12 months.


Shanghai Pharmaceuticals Holding Co Ltd ADR

1D
0.00%
1M
0.00%
YTD
-7.65%
6M
-6.69%
1Y
15.56%
3Y*
-4.17%
5Y*
-3.90%
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.25%
YTD
11.16%
6M
11.43%
1Y
28.20%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SHPMY Monthly Returns History

Based on dividend-adjusted daily data since Oct 9, 2017, SHPMY's average daily return is +0.04%, while the average monthly return is +0.08%. At this rate, an investment would double in approximately 72.2 years.

Historically, 41% of months were positive and 59% were negative. The best month was Nov 2022 with a return of +21.3%, while the worst month was Apr 2022 at -20.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, SHPMY closed higher 29% of trading days. The best single day was Mar 21, 2022 with a return of +26.4%, while the worst single day was Mar 24, 2020 at -13.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20260.00%-14.09%7.50%0.00%0.00%0.00%-7.65%
2025-7.02%-6.19%0.69%-6.69%0.00%0.00%20.39%0.00%3.75%-0.84%0.00%1.04%2.54%
20241.60%13.03%-11.59%3.09%2.80%-4.02%9.19%-12.44%20.43%0.44%5.09%-3.17%21.54%
20238.95%1.31%4.50%7.12%-2.29%-0.31%-0.23%-10.33%-7.02%-4.31%-0.87%-2.65%-7.55%
20223.13%-7.76%12.46%-20.18%5.22%-4.96%-1.05%-3.28%-4.78%-0.95%21.33%-0.89%-7.32%
20210.48%5.48%15.59%11.05%-0.53%-3.54%-0.01%-6.76%3.06%-9.95%1.26%3.13%17.96%

Benchmark Metrics

Shanghai Pharmaceuticals Holding Co Ltd ADR has an annualized alpha of 6.00%, beta of 0.20, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 11, 2017.

  • This stock participated in 93.45% of S&P 500 Index downside but only 36.60% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.20 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
6.00%
Beta
0.20
0.01
Upside Capture
36.60%
Downside Capture
93.45%

Return for Risk

Risk / Return Rank

SHPMY ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


SHPMY Risk / Return Rank: 6868
Overall Rank
SHPMY Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
SHPMY Sortino Ratio Rank: 5656
Sortino Ratio Rank
SHPMY Omega Ratio Rank: 9696
Omega Ratio Rank
SHPMY Calmar Ratio Rank: 6262
Calmar Ratio Rank
SHPMY Martin Ratio Rank: 6464
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Shanghai Pharmaceuticals Holding Co Ltd ADR (SHPMY) and compare them to S&P 500 Index.


SHPMYBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.61

2.39

-1.78

Sortino ratio

Return per unit of downside risk

1.11

3.25

-2.15

Omega ratio

Gain probability vs. loss probability

1.63

1.43

+0.19

Calmar ratio

Return relative to maximum drawdown

1.11

3.11

-2.00

Martin ratio

Return relative to average drawdown

2.82

14.38

-11.56

Dividends

Dividend History

Shanghai Pharmaceuticals Holding Co Ltd ADR provided a 3.78% dividend yield over the last twelve months, with an annual payout of $0.29 per share.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%$0.00$0.10$0.20$0.30$0.40$0.50$0.602019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM2025202420232022202120202019
Dividend$0.29$0.29$0.34$0.42$0.63$0.37$0.25$0.24

Dividend yield

3.78%3.49%4.06%5.87%7.70%3.89%2.94%2.41%

Monthly Dividends

The table displays the monthly dividend distributions for Shanghai Pharmaceuticals Holding Co Ltd ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2025$0.00$0.00$0.00$0.00$0.00$0.00$0.20$0.00$0.00$0.00$0.00$0.08$0.29
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.28$0.00$0.06$0.00$0.00$0.00$0.34
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.42$0.00$0.00$0.00$0.00$0.00$0.42
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.63$0.00$0.00$0.00$0.00$0.00$0.63
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.37$0.00$0.00$0.00$0.00$0.00$0.37

Dividend Yield & Payout


Dividend Yield

Shanghai Pharmaceuticals Holding Co Ltd ADR has a dividend yield of 3.78%, which is quite average when compared to the overall market.

Payout Ratio

Shanghai Pharmaceuticals Holding Co Ltd ADR has a payout ratio of 26.74%, which is quite average when compared to the overall market. This suggests that Shanghai Pharmaceuticals Holding Co Ltd ADR strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Shanghai Pharmaceuticals Holding Co Ltd ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Shanghai Pharmaceuticals Holding Co Ltd ADR was 53.72%, occurring on Mar 18, 2020. The portfolio has not yet recovered.

The current Shanghai Pharmaceuticals Holding Co Ltd ADR drawdown is 32.45%.


Related event

Drawdown

Fall

Recovery

Underwater

COVID crash2020
-53.72%Mar 2020
1y 10mo
8y 1moMay 2018 - now
2018 correction2018
-11.67%Feb 2018
0s2mo
2moFeb 2018 - Apr 2018
2017 pullback2017
-4.44%Nov 2017
0s1mo 19d
1mo 19dNov 2017 - Jan 2018

Drawdown Indicators


SHPMYBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-53.72%

-56.78%

+3.06%

Max Drawdown (1Y)

Largest decline over 1 year

-14.09%

-9.10%

-4.99%

Max Drawdown (3Y)

Largest decline over 3 years

-36.47%

-18.90%

-17.57%

Max Drawdown (5Y)

Largest decline over 5 years

-38.27%

-25.43%

-12.84%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-32.45%

0.00%

-32.45%

Average Drawdown

Average peak-to-trough decline

-34.23%

-10.72%

-23.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.52%

1.97%

+3.55%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Shanghai Pharmaceuticals Holding Co Ltd ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Shanghai Pharmaceuticals Holding Co Ltd ADR is priced in the market compared to other companies in the Medical Distribution industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for SHPMY, comparing it with other companies in the Medical Distribution industry. Currently, SHPMY has a P/E ratio of 1.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for SHPMY relative to other companies in the Medical Distribution industry. Currently, SHPMY has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for SHPMY in comparison with other companies in the Medical Distribution industry. Currently, SHPMY has a P/B value of 0.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with SHPMY

Add Shanghai Pharmaceuticals Holding Co Ltd ADR to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with SHPMY